Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)

被引：0
|
作者：
Kawaguchi, H. [1 ,11 ]
Masuda, N. [2 ]
Nakayama, T. [3 ]
Aogi, K. [4 ]
Anan, K. [5 ]
Ito, Y. [6 ]
Ohtani, S. [7 ]
Sato, N. [8 ]
Saji, S. [9 ]
Tokunaga, E. [10 ]
Nakamura, S.
Hasegawa, Y. [12 ]
Hattori, M. [13 ]
Fujisawa, T. [14 ]
Morita, S. [15 ]
Yamaguchi, M. [16 ]
Yamashita, T. [17 ]
Yamamoto, Y. [18 ]
Ohno, S. [19 ]
Toi, M. [20 ]
机构：
[1] Matsuyama Red Cross Hosp, Breast Surg, Matsuyama, Ehime, Japan
[2] Osaka Natl Hosp, Dept Surg Breast Oncol, Osaka, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast & Endocrine Surg, Osaka, Japan
[4] Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan
[5] Kitakyushu Municipal Med Ctr, Dept Surg, Kitakyushu, Fukuoka, Japan
[6] Canc Inst Hosp JFCR, Breast Med Oncol Dept, Tokyo, Japan
[7] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg Hiroshima, Hiroshima, Japan
[8] Niigata Canc Ctr Hosp, Dept Breast Oncol, Niigata, Japan
[9] Fukushima Med Univ, Dept Med Oncol, Fukushima, Japan
[10] Kyushu Canc Ctr, Dept Breast Oncol, Fukuoka, Japan
[11] Showa Univ, Sch Med, Showa Univ Hosp, Dept Surg,Div Breast Surg Oncol, Tokyo 142, Japan
[12] Hirosaki Municipal Hosp, Dept Breast Surg, Hirosaki, Aomori, Japan
[13] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan
[14] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ohta, Gunma, Japan
[15] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan
[16] JCHO Kurume Gen Hosp, Dept Breast Surg, Kurume, Fukuoka, Japan
[17] Komagome Hosp, Dept Breast Surg, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[18] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan
[19] Canc Inst Hosp JFCR, Breast Oncol Ctr, Tokyo, Japan
[20] Kyoto Univ, Dept Breast Surg, Grad Sch Med, Kyoto, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
379
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 48 条
  • [31] ACT-FASTER, a Prospective Cohort Study Exploring Treatment Patterns with Fulvestrant and Exemestane in Postmenopausal Patients with Advanced Hormone Receptor-Positive Breast Cancer under Real-Life Conditions in Germany
    Maass, Nicolai
    Ostermann, Helmut
    Possinger, Kurt
    Klein, Peter
    Tesch, Hans
    Muehlenhoff, Lars
    Bauerschlag, Dirk O.
    BREAST CARE, 2019, 14 (06) : 401 - 408
  • [32] Dolaf- an international multicenter phase 2 trial of durvalumab (medi4736) plus olaparib plus fulvestrant in metastatic or locally advanced er-positive, her2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib (UCBG308)
    Guiu, Severine
    Balmana, Judith
    Roca, Lise
    Goncalves, Anthony
    Mailliez, Audrey
    Bigot, Frederic
    Bachelot, Thomas
    Dalenc, Florence
    Dohollou, Nadine
    Genet, Dominique
    Desmoulins, Isabelle
    Chakiba, Camille
    Delaloge, Suzette
    Martineau, Geraldine
    Haddad, Veronique
    Follana, Philippe
    CANCER RESEARCH, 2021, 81 (04)
  • [33] Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
    Pestalozzi, Bernhard C.
    Tausch, Christoph
    Dedes, Konstantin J.
    Rochlitz, Christoph
    Zimmermann, Stefan
    von Moos, Roger
    Winterhalder, Ralph
    Ruhstaller, Thomas
    Mueller, Andreas
    Buser, Katharina
    Borner, Markus
    Novak, Urban
    Nussbaum, Catrina Uhlmann
    Seifert, Bettina
    Bigler, Martin
    Bize, Vincent
    Vilei, Simona Berardi
    Rageth, Christoph
    Aebi, Stefan
    BMC CANCER, 2017, 17
  • [34] Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
    Bernhard C. Pestalozzi
    Christoph Tausch
    Konstantin J. Dedes
    Christoph Rochlitz
    Stefan Zimmermann
    Roger von Moos
    Ralph Winterhalder
    Thomas Ruhstaller
    Andreas Mueller
    Katharina Buser
    Markus Borner
    Urban Novak
    Catrina Uhlmann Nussbaum
    Bettina Seifert
    Martin Bigler
    Vincent Bize
    Simona Berardi Vilei
    Christoph Rageth
    Stefan Aebi
    BMC Cancer, 17
  • [35] Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD)
    Yamashita, Toshinari
    Saji, Shigehira
    Takano, Toshimi
    Naito, Yoichi
    Tsuneizumi, Michiko
    Yoshimura, Akiyo
    Takahashi, Masato
    Tsurutani, Junji
    Iwatani, Tsuguo
    Kitada, Masahiro
    Tada, Hiroshi
    Mori, Natsuko
    Higuchi, Toru
    Iwasa, Tsutomu
    Araki, Kazuhiro
    Sakai, Kazuko
    Hasegawa, Hiroki
    Uchida, Yohei
    Morita, Satoshi
    Masuda, Norikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2-advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study
    Wang, J.
    Xu, B.
    Cai, L.
    Song, Y.
    Kang, L.
    Sun, T.
    Teng, Y.
    Tong, Z.
    Li, H.
    Ouyang, Q.
    Cui, S.
    Yan, M.
    Chen, Q.
    Yin, Y.
    Sun, Q.
    Liao, N.
    Feng, J.
    Wang, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S461 - S462
  • [37] Baseline results from ACT-FASTER, a prospective cohort study exploring treatment patterns with fulvestrant and exemestane in postmenopausal patients with advanced hormone-receptor positive breast cancer under real-life conditions in Germany
    Ostermann, H.
    Maass, N.
    Possinger, K.
    Tesch, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 264 - 264
  • [38] Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)
    Roylance, Rebecca
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Macpherson, Iain
    Baird, Richard D.
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Ring, Alistair
    Bliss, Judith M.
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [39] SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease
    Andre, Fabrice
    Im, Seock-Ah
    Neven, Patrick
    Baird, Richard D.
    Ettl, Johannes
    Goetz, Matthew P.
    Hamilton, Erika
    Iwata, Hiroji
    Jiang, Zefei
    Joy, Anil Abraham
    Haddad, Vincent
    Walding, Andrew
    Miralles, Manuel Selvi
    Bartlett, Cynthia Huang
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2022, 82 (04)
  • [40] SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
    Im, Seock-Ah
    Hamilton, Erika P.
    Cussac, Antonio Llombart
    Baird, Richard D.
    Ettl, Johannes
    Goetz, Matthew P.
    Iwata, Hiroji
    Joy, Anil Abraham
    Neven, Patrick
    Haddad, Vincent
    Walding, Andrew Stephen
    Miralles, Manuel Selvi
    Bartlett, Cynthia Huang
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345